Medikamentöse Therapie von Hirntumoren

B. E. Stopschinski; D. Beier; C. P. Beier

doi:10.1055/s-0038-1628288

Nervenheilkunde, Inhaltsverzeichnis

Nervenheilkunde 2012; 31(09): 621-629
DOI: 10.1055/s-0038-1628288

Neuroonkologie

Schattauer GmbH

Medikamentöse Therapie von Hirntumoren

Medicinal therapy of brain tumors

Autoren

B. E. Stopschinski

¹Neurologische Universitätsklinik, RWTH Aachen
D. Beier

¹Neurologische Universitätsklinik, RWTH Aachen
C. P. Beier

¹Neurologische Universitätsklinik, RWTH Aachen

Abstract

Zusammenfassung

Die Chemotherapie zählt zur Standardtherapie vieler Hirntumore. In der Behandlung der häufigsten Hirntumore, den zerebralen Gliomen, kommt der Chemotherapie ein wichtiger Stellenwert zu. Studien untersuchen die prognostische und therapeutische Relevanz verschiedener molekularer Marker in der Gliomtherapie, wie den LOH-1p/19q-Status, Mutationen des Isocitratdehydrogenasegens sowie die Methylierung des MGMT-Promotors. Neue Substanzen aus dem Bereich der Immuntherapie, der Virotherapie und der Angiogenesehemmung werden auf ihre Wirksamkeit in vorklinischen und klinischen Studien überprüft. Für die selteneren Hirntumore, wie die pilozytischen Astrozytome, Ependymome und Medulloblastome fehlen größere Studien zur Relevanz der Chemotherapie. Sie nimmt jedoch eine Schlüsselrolle in der Therapie der primären ZNS-Lymphome ein.

Summary

Chemotherapy has become part of the standard treatment for many brain tumors. It plays an important role in the therapy oft the most common brain tumors, the gliomas. Several ongoing studies investigate the prognostic and therapeutic relevance of different molecular markers in glioma therapy, such as the LOH 1p/19q status or the presence of isocitrate dehydrogenase mutations and MGMT promoter methylation. New therapeutic approaches from immunotherapy, virotherapy, and inhibition of angiogenesis are currently under investigation in preclinical and clinical studies. For the more seldom-occurring brain tumors, such as pilocytic astrocytomas, ependymomas and medulloblastomas, large studies concerning the relevance of chemotherapy are lacking. However, chemotherapy plays a key role in the treatment of primary CNS lymphomas.

Schlüsselwörter

Neuroonkologie - Chemotherapie - Hirntumor - Temozolomid - Glioblastom - LOH 1p/19q - IDH1 - MGMT

Keywords

Neurooncology - chemotherapy - brain tumor - temozolomide - glioblastoma - LOH 1p/19q - IDH1 - MGMT

Volltext

Referenzen

Literatur
1 Stupp R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England J Med 2005; 352 (10) 987-96.
2 Ferreri AJ, Marturano E. Primary CNS lymphoma. Best practice & research Clinical haematology 2012; 25 (Suppl. 01) 119-30.
3 Weller M. [Chemotherapy for brain tumors in adult patients]. Der Nervenarzt 2008; 79 (Suppl. 02) 231-41.
4 Tabatabai G, Hegi M, Stupp R, Weller M. Clinical implications of molecular neuropathology and biomarkers for malignant glioma. Current Neurology and Neuroscience Reports 2012; 12 (Suppl. 03) 302-7.
5 Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994; 145 (Suppl. 05) 1175-90.
6 Cairncross G. et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24 (18) 2707-14.
7 Van den Bent MJ. et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24 (18) 2715-22.
8 Ino Y. et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7 (Suppl. 04) 839-45.
9 Houillier C. et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006; 106 (10) 2218-23.
10 Parsons DW. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321 5897 1807-12.
11 Dang L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462 7274 739-44.
12 Wick W. et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27 (35) 5874-80.
13 Hartmann C. et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta neuropathologica 2010; 120 (Suppl. 06) 707-18.
14 Thon N. et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 2012; 118 (Suppl. 02) 452-60.
15 Hegi ME. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New England J Med 2005; 352 (10) 997-1003.
16 Reifenberger G. et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. J Int du Cancer. 2011: 125.
17 Gilbert MR, Wang M. A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). ASCO Meeting Abstracts 2011; 29: 2006.
18 Karim AB. et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiation Oncology, Biology, Physics 1996; 36 (Suppl. 03) 549-56.
19 Karim AB. et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiation Oncology, Biology, Physics 2002; 52 (Suppl. 02) 316-24.
20 Weller M. Gliome. DGN Leitlinien. Berlin: Deutsche Gesellschaft für Neurologie; 2008
21 Bauman G. et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiation Oncology, Biology, Physics 1999; 45 (Suppl. 04) 923-9.
22 Van den Bent MJ. et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005; 366 9490 985-90.
23 Brandt T, Diener HC. Neoplasien und Missbildungen. Stuttgart: WKG; 2003
24 Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiotherapy and oncology. J Eur Soc Therapeutic Radiology and Oncology 2002; 64 (Suppl. 03) 259-73.
25 Donahue B. et al. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83–02. Int J Radiation Oncology, Biology, Physics 1997; 38 (Suppl. 05) 911-4.
26 Yung WK. et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. British Journal of Cancer 2000; 83 (Suppl. 05) 588-93.
27 Yung WK. et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999; 17 (Suppl. 09) 2762-71.
28 Reardon DA. et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. British Journal of Cancer 2009; 101 (12) 1995-2004.
29 Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosis cerebri to temozolomide and whole brain radiotherapy. Clinical Neurology and Neurosurgery 2012; 114 (Suppl. 04) 299-306.
30 Herrlinger U. et al. Gliomatosis cerebri: molecular pathology and clinical course. Annals of Neurology 2002; 52 (Suppl. 04) 390-9.
31 Sanson M. et al. Initial chemotherapy in gliomatosis cerebri. Neurology 2004; 63 (Suppl. 02) 270-5.
32 Glas M. et al. NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Annals of Neurology 2011; 70 (Suppl. 03) 445-53.
33 Hau P. et al. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 2007; 68 (Suppl. 09) 688-90.
34 Beier CP. et al. RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma – a phase II study. BMC Cancer 2009; 9: 308.
35 Clarke JL. et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 2009; 27 (23) 3861-7.
36 Weller M, Muller B, Koch R, Bamberg M, Krause-neck P. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 2003; 21 (17) 3276-84.
37 Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochirurgica 2006; 148 (Suppl. 03) 269-75.
38 Glas M. et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009; 27 (Suppl. 08) 1257-61.
39 Wick W. et al. NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). J Clin Oncol 2010; 28: 18s.
40 Gallego Perez-Larraya J. et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011; 29 (22) 3050-5.
41 Perry JR. et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 2010; 28 (12) 2051-7.
42 Wick W. et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010; 28 (Suppl. 07) 1168-74.
43 Gilbert MR. Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches. Seminars in oncology 2011; 38 Suppl 4: 21-33.
44 Vredenburgh JJ. et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clinical cancer research. J Am Association for Cancer Research 2007; 13 (Suppl. 04) 1253-9.
45 Chinot O. et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Advances in therapy 2011; 28 (Suppl. 04) 334-40.
46 Stupp R. et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28 (16) 2712-8.
47 Aigner L, Bogdahn U. TGF-beta in neural stem cells and in tumors of the central nervous system. Cell and tissue research 2008; 331 (Suppl. 01) 225-41.
48 Bogdahn U. et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-oncology 2011; 13 (Suppl. 01) 132-42.
49 Finocchiaro G, Pellegatta S. Immunotherapy for glioma: getting closer to the clinical arena?. Current opinion in neurology 2011; 24 (Suppl. 06) 641-7.
50 Kroeger KM. et al. Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discovery medicine 2010; 10 (53) 293-304.
51 Van Putten EH, Dirven CM, van den Bent MJ, Lamfers ML. Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. Future Oncol 2010; 6 (11) 1691-710.
52 Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. J Neuro-oncology 2011; 13 (Suppl. 06) 566-79.
53 Brown PD. et al. Adult patients with supratentorial pilocytic astrocytomas: a prospective multicenter clinical trial. Int J Radiation Oncology, Biology, Physics 2004; 58 (Suppl. 04) 1153-60.
54 Kortmann RD. et al. Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part I: Treatment modalities of radiation therapy. Strahlentherapie und Onkologie. Organ der Deutschen Rontgengesellschaft 2003; 179 (Suppl. 08) 509-20.
55 Gilbert MR, Ruda R, Soffietti R. Ependymomas in adults. Current neurology and neuroscience reports 2010; 10 (Suppl. 03) 240-7.
56 McGuire CS, Sainani KL, Fisher PG. Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurgery 2009; 110 (Suppl. 04) 725-9.
57 Creutzig U. LT. Ependymome. AWMF Leitlinien. Düsseldorf: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften; 2010
58 Metellus P. et al. Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain 2007; 130 Pt 5 1338-49.
59 Chamberlain MC, Johnston SK. Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma. Cancer 2009; 115 (20) 4775-82.
60 Gornet MK, Buckner JC, Marks RS, Scheithauer BW, Erickson BJ. Chemotherapy for advanced CNS ependymoma. J Neuro-oncology 1999; 45 (Suppl. 01) 61-7.
61 Brandes AA. et al. A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Coop-erativo di Neuro-Oncologia. Cancer 2005; 104 (Suppl. 01) 143-8.
62 Green RM. et al. Bevacizumab for recurrent ependymoma. Neurology 2009; 73 (20) 1677-80.
63 Fellay CN. et al. Medulloblastomas in adults: prognostic factors and lessons from paediatrics. Current Opinion in Neurology 2011; 24 (Suppl. 06) 626-32.
64 Creutzig U. LT. Medulloblastom im Kinder- und Jugenalter. AWMF Leitlinien. Düsseldorf: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften; 2008
65 Taylor RE. et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study. J Clin Oncol 2003; 21 (Suppl. 08) 1581-91.
66 Zeltzer PM. et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 1999; 17 (Suppl. 03) 832-45.
67 Kortmann RD. et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT ‘91. Int J Radiation Oncology, Biology, Physics 2000; 46 (Suppl. 02) 269-79.
68 Riffaud L. et al. Survival and prognostic factors in a series of adults with medulloblastomas. J Neurosurgery 2009; 111 (Suppl. 03) 478-87.
69 Chan AW. et al. Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery 2000; 47 (Suppl. 03) 623-31.
70 Padovani L. et al. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiation Oncology, Biology, Physics 2007; 68 (Suppl. 02) 433-40.
71 Herrlinger U. et al. Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse. J Neurology 2005; 252 (Suppl. 03) 291-9.
72 Schlegel U. Primäre ZNS-Lymphome leitlinien (PZNSL). Berlin: Deutsche Gesellschaft für Neurologie; 2008
73 Herrlinger U. et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Annals of Neurology 2005; 57 (Suppl. 06) 843-7.
74 Ferreri AJ. et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374 9700 1512-20.
75 Pels H. et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003; 21 (24) 4489-95.
76 Illerhaus G. et al. High-dose chemotherapy with autologous stem-cell transplantation and hyper-fractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24 (24) 3865-70.
77 Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neuro-oncology 1999; 43 (Suppl. 03) 241-7.
78 Reni M. et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiation Oncology, Biology, Physics 2001; 51 (Suppl. 02) 419-25.
79 Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16 (Suppl. 03) 859-63.
80 Thiel E. et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11 (11) 1036-47.
81 Soussain C, Hoang-Xuan K, Levy V. [Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma]. Bulletin du Cancer 2004; 91 (Suppl. 02) 189-92.
82 Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005; 23 (Suppl. 07) 1507-13.
83 Plotkin SR. et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clinical cancer research. J Am Association for Cancer Research 2004; 10 (17) 5643-6.
84 Reni M. et al. Temozolomide as salvage treatment in primary brain lymphomas. British J Cancer 2007; 96 (Suppl. 06) 864-7.
85 Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004; 63 (Suppl. 05) 901-3.
86 Fischer L, Thiel E, Klasen HA, Kirchen H, Jahnke K, Korfel A. Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 2004; 62 (10) 1885-7.